Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 18
2002 47
2003 89
2004 83
2005 106
2006 124
2007 170
2008 223
2009 292
2010 269
2011 290
2012 310
2013 286
2014 316
2015 339
2016 327
2017 306
2018 327
2019 282
2020 317
2021 306
2022 267
2023 279
2024 330
2025 172
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,168 results

Results by year

Filters applied: . Clear all
Page 1
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.
Lamb YN. Lamb YN. Am J Cardiovasc Drugs. 2020 Aug;20(4):381-392. doi: 10.1007/s40256-020-00421-1. Am J Cardiovasc Drugs. 2020. PMID: 32648167 Review.
In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvastatin/ezetimibe was significantly more effective than rosuvastatin monotherapy (including at double the …
In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents …
Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis.
Jaam M, Al-Naimi HN, Haddad MM, Abushanab D, Al-Badriyeh D. Jaam M, et al. J Comp Eff Res. 2023 Mar;12(3):e220163. doi: 10.57264/cer-2022-0163. Epub 2023 Feb 27. J Comp Eff Res. 2023. PMID: 36847307 Free PMC article. Review.
Based on a pooled quantitative analysis of atorvastatin 80 mg versus rosuvastatin 40 mg, rosuvastatin was statistically more effective in reducing LDL. Conclusion: This review further confirms that high-intensity statins reduce LDL by 50%, favoring rosuvastatin …
Based on a pooled quantitative analysis of atorvastatin 80 mg versus rosuvastatin 40 mg, rosuvastatin was statistically more e …
Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin : A Multi-database Cohort Study.
Zhou S, Chen R, Liu J, Guo Z, Su L, Li Y, Zhang X, Luo F, Gao Q, Lin Y, Pang M, Cao L, Xu X, Nie S. Zhou S, et al. Ann Intern Med. 2024 Dec;177(12):1641-1651. doi: 10.7326/M24-0178. Epub 2024 Oct 29. Ann Intern Med. 2024. PMID: 39467290
BACKGROUND: Rosuvastatin and atorvastatin are the most widely prescribed moderate- to high-intensity statins. ...For secondary outcomes in both databases, rosuvastatin conferred lower risks for major adverse cardiovascular events and major adverse liver outcomes. .. …
BACKGROUND: Rosuvastatin and atorvastatin are the most widely prescribed moderate- to high-intensity statins. ...For secondary outcom …
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
Zheng H, Li H, Wang Y, Li Z, Hu B, Li X, Fu L, Hu H, Nie Z, Zhao B, Wei D, Karlson BW, Bots ML, Meng X, Chen Y, Wang Y; METEOR-China Investigators. Zheng H, et al. Stroke. 2022 Oct;53(10):3004-3013. doi: 10.1161/STROKEAHA.120.031877. Epub 2022 Aug 26. Stroke. 2022. PMID: 36017704 Free PMC article. Clinical Trial.
RESULTS: Participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well balanced between groups. ...There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-e …
RESULTS: Participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well ba …
Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations.
Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Zhang L, et al. Herz. 2020 Sep;45(6):594-602. doi: 10.1007/s00059-018-4767-2. Epub 2018 Nov 27. Herz. 2020. PMID: 30483816 English.
Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events. CONCLUSION: Similar to the VOYAGER meta-analysis, which reported a greater efficacy of rosuvastatin in comparison with atorvastatin and simvastatin in Caucasian patien …
Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events. CONCLUSION: Similar to the VOYAGER …
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Chilbert MR, et al. Drug Des Devel Ther. 2022 Jul 7;16:2177-2186. doi: 10.2147/DDDT.S332352. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35832642 Free PMC article. Review.
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We aimed t …
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial …
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, Hong SJ, Ahn JC, Sung JH, Cho JM, Lee HC, Choi SY, Lee K, Kim WS, Rhee MY, Kim JH, Hong SP, Yoo BS, Cho EJ, Lee JH, Kim PJ, Park CG, Hyon MS, Shin JH, Lee SH, Sung KC, Hwang J, Kwon K, Chae IH, Seo JS, Kim H, Lee H, Cho Y, Kim HS. Jin X, et al. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1835-1845. doi: 10.1111/jch.13893. Epub 2020 Sep 16. J Clin Hypertens (Greenwich). 2020. PMID: 32937023 Free PMC article. Clinical Trial.
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. ...The Least-Square (LS) mean (SE) for changes in MSS …
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 …
Rosuvastatin pharmacogenetics in African populations.
Soko ND, Masimirembwa C, Dandara C. Soko ND, et al. Pharmacogenomics. 2018 Dec;19(18):1373-1375. doi: 10.2217/pgs-2018-0168. Epub 2018 Nov 6. Pharmacogenomics. 2018. PMID: 30398065 No abstract available.
Perioperative Rosuvastatin in Cardiac Surgery.
Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B. Zheng Z, et al. N Engl J Med. 2016 May 5;374(18):1744-53. doi: 10.1056/NEJMoa1507750. N Engl J Med. 2016. PMID: 27144849 Free article. Clinical Trial.
RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to rosuvastatin than in those assigned to placebo (P<0.001). However, the rate of postoperative atrial fibrillation did not differ sig …
RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to …
Rosuvastatin: Beyond the cholesterol-lowering effect.
Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Cortese F, et al. Pharmacol Res. 2016 May;107:1-18. doi: 10.1016/j.phrs.2016.02.012. Epub 2016 Mar 2. Pharmacol Res. 2016. PMID: 26930419 Review.
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesi …
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively …
5,168 results